Ozempic®, Wegovy® and GLP-1 for PCOS: the evidence

If you have PCOS, you may wonder whether GLP-1 medicines like Ozempic® and Wegovy® could help.

Maybe a friend mentioned them, or you saw a story online. Now you want the plain facts, not the hype.

Here is the honest picture. The research is still early, and these medicines are not approved for PCOS. This guide shares what we do and do not know.

PCOS, weight, and insulin resistance

PCOS stands for polycystic ovary syndrome. It is a common hormone condition in women of reproductive age.

Many people with PCOS also have insulin resistance. That means the body does not respond to insulin as well as it should.

Extra weight can make insulin resistance harder to manage. This is one reason weight and metabolic health come up so often in PCOS care.

Even a modest weight change can ease some of these strains. That is part of why weight often shows up in PCOS treatment plans.

GLP-1 medicines act on this same system. They can lower appetite and support weight loss, which is why researchers have studied them in PCOS.

Are Ozempic® and Wegovy® approved for PCOS?

Here is the key point, stated plainly. Ozempic® and Wegovy® are not FDA-approved for PCOS.

PCOS is not listed in the approved uses for either medicine. So any use for PCOS is called off-label.

Off-label means a doctor may prescribe a medicine for a use the FDA has not approved. It is legal, and it is a decision made with your doctor.

This guide does not tell you whether to use them. It explains the evidence so you can have a better talk with your doctor.

Ozempic® and Wegovy® are not FDA-approved for PCOS, so any use for PCOS is off-label and belongs in a talk with your doctor.

What Ozempic® and Wegovy® are actually approved for

Each brand has its own approved use. Both are forms of semaglutide, a GLP-1 receptor agonist taken as a once-weekly shot.

Ozempic® is approved to help manage blood sugar in adults with type 2 diabetes. It is not approved for weight loss.

Wegovy® is approved for chronic weight management in certain adults. It is used along with diet and more activity. These results apply only to the FDA-approved branded product and do not transfer to compounded preparations.

Both brands start at a low dose and step up slowly over weeks. This gentle climb gives your body time to adjust.

In its STEP 1 trial, Wegovy® 2.4 mg was tested in 1,961 adults. People on Wegovy® lost about 14.9% of body weight at 68 weeks, versus 2.4% on placebo.

That trial was in adults with obesity, not in PCOS. Still, it shows why weight change is central to how Wegovy® works.

Because both brands are semaglutide, people sometimes assume they are interchangeable. They are not, since each is approved for a different use at a different dose.

What research on GLP-1 and PCOS shows for Ozempic® and Wegovy®

The direct PCOS research is still small and early. Most of it studies GLP-1 receptor agonists as a class.

That class includes Ozempic® and Wegovy®. So many trials do not test one brand by itself.

A 2025 meta-analysis pooled 13 randomized trials. It included 397 women with PCOS who received a GLP-1 receptor agonist.

In that analysis, body weight fell about 3.57 kg (95% CI 1.99 to 5.15). BMI dropped about 1.59 kg/m2 (95% CI 1.10 to 2.07).

Waist size fell about 4.97 cm. A marker of insulin resistance called HOMA-IR dropped about 0.58 (95% CI 0.19 to 0.98).

HOMA-IR is a simple score from blood tests. A lower score points to better insulin sensitivity, which many people with PCOS are working toward.

These changes were measured against control groups. They suggest GLP-1 receptor agonists may support modest weight and metabolic improvements in PCOS.

The word modest matters here. These are helpful signals, not dramatic changes, and they come from a small pool of people.

In a 2025 meta-analysis of 13 trials, 397 women with PCOS saw body weight fall about 3.57 kg with GLP-1 receptor agonists.

Where the PCOS evidence still falls short

It helps to be clear about the limits. The PCOS research is early, and the studies are small.

The 2025 meta-analysis included only 397 women who received the medicines. That is a small group on which to base firm conclusions.

Most trials looked at weight and metabolic markers. They did not track long-term outcomes, and they were not designed to test PCOS as a whole.

Another limit is the mix of medicines studied. The trials pooled different GLP-1 receptor agonists, not one brand on its own.

There is also no approved GLP-1 dose or plan for PCOS. So many practical questions are still open.

None of this means the medicines cannot help. The evidence is simply not yet strong enough to make broad claims.

The PCOS evidence is early and small, so the honest answer is that we are still learning.

What these medicines do not claim in PCOS

It is just as important to know what the evidence does not say. Clear limits protect you from hype.

These medicines are not a cure for PCOS. No medicine cures PCOS today, and GLP-1 medicines are no different.

The PCOS studies here focused on weight and metabolic markers. They were not designed to answer questions about fertility or pregnancy.

Weight and insulin markers are only part of PCOS care. Diet, activity, sleep, and other treatments all play a role too.

Safety questions to keep in mind

Every medicine has trade-offs, and GLP-1 medicines are no exception. The most serious warning is the boxed thyroid warning covered above.

In the PCOS studies, stomach side effects were more common with GLP-1 receptor agonists. These include nausea, vomiting, and diarrhea.

Both labels also warn about acute pancreatitis, a serious problem with the pancreas. Warning signs include severe stomach pain that may spread to your back.

If you notice pain like that, get medical care. Do not try to wait it out.

Starting low and going slow is meant to keep side effects gentler. Many people find stomach effects ease over time.

Side effects and your full health history both matter. This is one more reason a doctor should guide any decision.

How the approved evidence compares to the PCOS evidence

It can help to see the two kinds of evidence side by side. One is strong and approved, the other is early and off-label.

Topic	Approved evidence (Wegovy®)	PCOS evidence (GLP-1 class)
FDA approval	Wegovy® for chronic weight management; Ozempic® for type 2 diabetes	Not FDA-approved for PCOS (off-label use)
Main study	STEP 1, N=1,961, 68 weeks	2025 meta-analysis, 13 trials, 397 GLP-1RA recipients
Weight result	Wegovy® 2.4 mg about -14.9% vs -2.4% placebo	About -3.57 kg body weight vs control
Metabolic marker	Approved for blood sugar (Ozempic®, type 2 diabetes)	HOMA-IR about -0.58; BMI about -1.59 kg/m2
Evidence strength	Large, FDA-reviewed trials	Small and early, limited data

Figures come from the FDA prescribing information, the STEP 1 trial, and a 2025 PCOS meta-analysis. These are separate studies, not a head-to-head comparison.

The gap is clear. The approved uses rest on large trials, while the PCOS picture rests on early, smaller studies.

What talking to your doctor might look like

There is no set script for these talks. Still, a conversation about Ozempic® or Wegovy® and PCOS often follows a few steps.

1. Your doctor reviews your PCOS symptoms, your health history, and your goals.

2. You talk through what Ozempic® and Wegovy® are approved for, and what off-label use means.

3. You go over the early PCOS evidence, including its small size and limits.

4. You discuss safety, from the boxed thyroid warning to common stomach side effects.

5. Together you decide next steps, which may or may not include a GLP-1 medicine.

Questions to bring to your doctor

A little prep makes these talks easier. You do not need to know the science, just what to ask.

You do not need to know the science. You just need a few clear questions and an honest talk with your doctor.

3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021. PMID 33567185.

Frequently asked questions

Given my PCOS and health history, do Ozempic® or Wegovy® make sense for me?

What would we hope to improve, and how would we track it?

What side effects should I watch for, and when should I call you?

How does off-label use affect my follow-up and coverage?

What other PCOS options should we weigh at the same time?

There are no wrong questions here. The goal is a shared plan that fits your health and your life.

Are Ozempic® and Wegovy® approved for PCOS?

No. Ozempic® and Wegovy® are not FDA-approved for PCOS. PCOS is not listed in the approved uses for either medicine. Ozempic® is approved for type 2 diabetes, and Wegovy® is approved for chronic weight management. A doctor may still prescribe them off-label, which means for a use the FDA has not approved. That decision belongs to you and your doctor.

What does the research say about GLP-1 medicines and PCOS?

The research is early and small. A 2025 meta-analysis pooled 13 randomized trials with 397 women who received a GLP-1 receptor agonist. Body weight fell about 3.57 kg, BMI about 1.59 kg/m2, and waist size about 4.97 cm. A marker of insulin resistance, HOMA-IR, dropped about 0.58. These are modest changes from a small group, so they are promising but not proof.

Do Ozempic® or Wegovy® cure PCOS?

No. There is no cure for PCOS, and these medicines are not a treatment for it. The early studies looked at weight and metabolic markers, not PCOS as a whole. Any weight or insulin changes may help with certain PCOS-related concerns, but the evidence is limited. PCOS care is usually a mix of steps, so talk with your doctor about the full picture.

Are there side effects I should know about?

Yes. The most serious is a boxed warning about thyroid C-cell tumors, seen in animal studies. It is not known whether this risk carries to people. Both labels also warn about acute pancreatitis, which can cause severe stomach pain that may spread to the back. In the PCOS studies, stomach effects like nausea, vomiting, and diarrhea were more common. Tell your doctor about any symptoms.

Why is the PCOS evidence called limited?

Because the studies are small and short. The 2025 meta-analysis included only 397 women who received the medicines, pooled from 13 trials. Most trials measured weight and metabolic markers, not long-term health. There is also no approved GLP-1 dose or plan for PCOS. So while the early signals look hopeful, researchers still need larger and longer studies before drawing firm conclusions.

What should I ask my doctor about GLP-1 medicines and PCOS?

Start with whether Ozempic® or Wegovy® fit your health history and goals. Ask what you would hope to improve and how you would track it. Ask which side effects to watch for and when to call. Because use in PCOS is off-label, ask how that affects follow-up and coverage. It also helps to weigh other PCOS options at the same time.

Important: This page is for education only and is not medical advice. Any medicines named here are available by prescription. Always talk to a licensed clinician about medicines, symptoms, or anything you are considering.